The State of Biosimilars in the United States: The Center for Biosimilars® Peer Exchange

January 24, 2018

The introduction of biosimilars to the US market has led to an unprecedented amount of uncertainty as stakeholders try to understand the implications of their arrival. In the following Peer Exchange discussion from The Center for Biosimilars®, held in September 2017, industry experts discuss regulation, policy, and litigation issues in the world of biosimilars.

The introduction of biosimilars to the US market has led to an unprecedented amount of uncertainty as stakeholders try to understand the implications of their arrival. The Center for Biosimilars®, a sister site of The American Journal of Managed Care®, serves as an online resource that brings together the worlds of clinical, business, regulatory, policy, and economic outcomes of biosimilars.

The introduction of biosimilars to the United States provides great promise, as they are expected to bring down the price of medications, but also challenges. Biosimilars face stringent regulatory requirements, continued education of patients and physicians, and ongoing litigation issues.

In the following Peer Exchange discussion from The Center for Biosimilars®, held in September 2017, industry experts discuss regulation, policy, and litigation issues in the world of biosimilars. For more insight into the world of biosimilar therapies, visit centerforbiosimilars.com.

Listen below or through one of these podcast services:

iTunes: http://apple.co/2eYWTss

TuneIn: http://bit.ly/2gv7iwj

Stitcher: http://bit.ly/2gCqtFg